Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2

Objectives: The efficacy of sofosbuvir plus ribavirin (RBV) treatment for hepatitis C virus (HCV) genotype 2 focusing on virological response was compared with that of pegylated interferon (peg-IFN) plus RBV treatment. Safety of the former focusing on the decline in hemoglobin levels was compared with that of the latter and assessed in terms of age and inosine triphosphatase (ITPA). Methods: Patients (n = 17) receiving sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV diagnosed with chronic HCV genotype 2 were enrolled in this study, and the efficacy and safety of both treatments were assessed. Results: Rapid virological response was attained with sofosbuvir plus RBV treatment compared with peg-IFN plus RBV treatment. All patients under sofosbuvir plus RBV treatment achieved end-of-treatment response compared with 70% who sustained viral response under the peg-IFN plus RBV treatment, with the former demonstrating greater virological response. The decline in hemoglobin levels under the former treatment was greater than that under the latter and in patients over 65 years of age with ITPA gene major. Conclusion: Efficacy and safety of sofosbuvir plus RBV treatment were clearly demonstrated compared with those of peg-IFN plus RBV treatment. The decline in hemoglobin levels was not related to the discontinuation of the former treatment, irrespective of age or the effect of the ITPA gene.

[1]  A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[2]  Jung-Hwan Yoon,et al.  Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea , 2015, Clinical and molecular hepatology.

[3]  M. Kudo,et al.  Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma , 2015, Oncology.

[4]  T. Murakami,et al.  Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe , 2015, Liver Cancer.

[5]  M. Kudo.  Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan , 2015, Liver Cancer.

[6]  T. Ide,et al.  Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial , 2014, Journal of viral hepatitis.

[7]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[8]  N. Enomoto,et al.  ITPA genetic variants influence efficacy of PEG‐IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type , 2014, Journal of viral hepatitis.

[9]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[10]  M. Kudo,et al.  Prediction of Response to Pegylated Interferon/Ribavirin Combination Therapy for Chronic Hepatitis C Genotypes 2a and 2b and High Viral Load , 2013, Digestive Diseases.

[11]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[12]  E. Schiff,et al.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.

[13]  N. Enomoto,et al.  Relationship between Polymorphisms of the Inosine Triphosphatase Gene and Anaemia or Outcome after Treatment with Pegylated Interferon and Ribavirin , 2011, Antiviral therapy.

[14]  N. Enomoto,et al.  ITPA gene variant protects against anemia induced by pegylated interferon‐α and ribavirin therapy for Japanese patients with chronic hepatitis C , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  K. Shianna,et al.  Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. , 2010, Gastroenterology.

[16]  Yusuke Nakamura,et al.  ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. , 2010, Gastroenterology.

[17]  Jacques Fellay,et al.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.

[18]  G. Borgstahl,et al.  Functional study of the P32T ITPA variant associated with drug sensitivity in humans. , 2009, Journal of molecular biology.

[19]  R. Pazdur,et al.  Sorafenib for the treatment of unresectable hepatocellular carcinoma. , 2009, The oncologist.

[20]  J. Sanderson,et al.  The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. , 2007, Biochimica et biophysica acta.

[21]  R. Hegele,et al.  DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency , 2002, Journal of Human Genetics.

[22]  J. Sanderson,et al.  Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency , 2002, Human Genetics.